Drugs and patents in ATC class L02B - HORMONE ANTAGONISTS AND RELATED AGENTS

Last updated: June 10, 2026

ATC L02B spans hormone antagonist and related therapies used in oncology, including androgen receptor (AR) pathway drugs, steroidogenesis inhibitors, and selective estrogen receptor (SERD/SERM-adjacent) assets depending on jurisdictional ATC mapping. Market structure is dominated by a small set of high-revenue oral small molecules and a smaller number of patented injectables and biologics. Patent estates typically include (1) composition-of-matter (MoC), (2) crystalline/formulation improvements, (3) method-of-use for new indications and combinations, and (4) manufacturing process patents. Patent expiry and exclusivity windows vary materially by molecule and by whether the asset is covered by US Hatch-Waxman exclusivities, pediatric exclusivity, and/or EU supplementary protection certificates (SPCs). The generic entry risk concentrates around US Paragraph IV certifications for tablets/capsules and around biosimilar pathways where L02B includes biologics in some product mappings.

Patent strategy summary for L02B

Most US blocking positions come from Orange Book-listed patents tied to MoC and formulation. Medical use patents are also common but are harder to attack because Paragraph IV is evaluated against the Orange Book listing tied to the FDA-approved conditions of use.
Many “late” patent expirations are driven by line extensions: polymorph/crystal form, salt, particle size, and dosing regimen changes.
Settlement-driven “authorized generic” deals are frequent for oral oncologics where the sponsor has Orange Book listings and expects generic litigation.
For assets with only limited Orange Book coverage, later method-of-use patents can still constrain off-label use but do not always prevent label-compatible generics.

Which L02B hormone antagonist drugs drive revenue, and what patents protect them?

Featured list of major L02B revenue anchors (typical US market leadership)

Androgen receptor antagonists: apalutamide (oral), enzalutamide (oral), darolutamide (oral)
Steroidogenesis inhibitor: abiraterone acetate (oral)
Estrogen receptor antagonist/SERD-adjacent assets in ATC mappings (depending on classification practice): fulvestrant (injectable), elacestrant (oral, where mapped), and other SERDs/SERMs depending on local ATC interpretation
Other hormone pathway agents included in L02B mappings in some references: gonadotropin-releasing hormone antagonists/agonists (less consistent across ATC sub-schemes)

How L02B patent estates typically break down

MoC patents: cover the active pharmaceutical ingredient (API) and stereochemistry
Salt/crystal form patents: cover polymorphs, hydrates/solvates, and controlled particle size distributions
Formulation patents: controlled release coatings, solid dispersion matrices, and excipient systems
Method-of-use patents: new disease stages, lines of therapy, combinations with ADT, chemotherapy, or immune-oncology agents
Process patents: purification steps, crystallization conditions, and scalable manufacturing improvements

US blocking mechanism

If FDA lists patents in the Orange Book for the approved drug and conditions of use, Paragraph IV generic challenges focus on those listed patents.
If patents are not listed, generics can still enter label-compatible products after regulatory approval, subject to injunction risk if there is separate enforcement against non-Orange Book patents.

How long does exclusivity last for L02B drugs, and when do patents expire?

Exclusivity layers that matter for L02B

Hatch-Waxman marketing exclusivity (NCE or new indication)
- NCE: typically 5 years (US)
- New indication exclusivity: typically 3 years
Patent term (MoC and process)
- Term runs from earliest effective filing date, adjusted by prosecution history and patent term adjustment (PTA)
Pediatric exclusivity
- Can extend patent term by 6 months for eligible assets
EU SPCs
- Extend protection for authorized medicinal products, generally tied to the first authorization in the EU plus duration rules

Timing dynamics seen across L02B

Many L02B assets have “staggered” expirations: MoC expires first, then formulation/polymorph patents and method-of-use patents extend the practical blocking window.
Line-extension portfolios often push the effective generic entry date later than MoC-only models predict.

Operational implication for investors and litigators

Exclusivity calendars must be built per label and per formulation strength because Orange Book listings can vary by dosage form and strength even for the same API.

What Orange Book status do L02B drugs have, and which patents are listed?

Orange Book status is the central map for US generic entry risk

High-risk products for early generic competition are those with extensive Orange Book listings across multiple patent families (MoC + formulation + method).
Moderate-risk products often have fewer Orange Book listings or fewer families covering the exact dosage form and strength.

Patent families usually show up as

“Drug substance” patents (MoC, including stereochemistry and polymorph)
“Drug product” patents (formulation, coating, and device-delivery aspects)
“Use” patents (often combinations and expanded indications)

Practical readout for business teams

Build a listing matrix: listed patent number, claim scope category (substance/product/use), expected expiration, and whether it is expiring early versus “late-stage” reformulations.

Which L02B drugs face Paragraph IV challenges, and what do litigation trends look like?

Paragraph IV challenge patterns in L02B

Oral oncologics in L02B attract frequent Paragraph IV filings because they are simplest to manufacture and require no complex biologics characterization.
Injectables in L02B (when included in the mapping) face fewer Paragraph IV filings but can still face device/formulation disputes and process patent enforcement.

Common litigation outcomes that influence market dynamics

Automatic 30-month stay after a compliant Paragraph IV filing (if triggered).
Early settlements that delay generic launch; settlement terms often include a “launch date” and sometimes non-at-risk supply limits.
Indefinite injunction risk depends on whether the court enjoins the specific act of infringement and whether the generic can design around method-of-use claims.

Commercial impact

Even when a generic is designed to avoid infringement of a subset of patents, sponsors can still enforce formulation and method-of-use patents if they are listed in the Orange Book or otherwise enforceable.

How strong is the patent estate for major L02B APIs like apalutamide, enzalutamide, darolutamide, and abiraterone?

How to assess estate strength (actionable scorecard for L02B)

Claim coverage breadth: whether patents cover the API + polymorph + formulation + method
Number of Orange Book listings: count and distribution across “drug substance,” “drug product,” and “use”
Litigation history: frequency of Paragraph IV filings and success in maintaining injunctions
Staggering: presence of late-expiring formulation/crystal-process patents that prolong the blocking window after MoC

Typical profile for top-tier L02B oncology orals

Multiple patent families and frequent line-extension filings
Frequent combination method-of-use patents
High likelihood that at least one family remains enforceable beyond the earliest MoC expiry

Investor/litigation decision point

For transaction due diligence, the estate is “strong” when Orange Book listings cover multiple dosage strengths and at least one formulation family has later expiry than the sponsor’s MoC core.

What formulations are protected for L02B drugs, and how does that affect generic design-around?

Formulation patent themes in L02B

Controlled-release or dissolution-modulating systems
Specific excipient sets tied to stability and bioavailability targets
Solid dispersion and particle engineering for exposure consistency
Crystalline form control, including hydrates/solvates and polymorph selection

Design-around constraints

Many generic challengers can match API but fail on formulation-specific claims if the sponsor has a formulation or polymorph patent that is hard to circumvent without altering the in vivo performance.
If the sponsor’s formulation patent is tightly tied to dissolution or bioequivalence targets, a generic may be forced into a costly development program.

Commercial knock-on

Formulation barriers can delay “at-risk” generic launches even when MoC patents fall away first.

Do L02B method-of-use patents block generics, and how often do they fail?

What method-of-use patents can do

They can block generics that seek approval for the same conditions of use covered by claims tied to the label (where listed in the Orange Book).
If not Orange Book-listed (or if claims are not tied to the approved labeling), enforcement can depend on non-Orange Book patent mechanisms.

How method-of-use patents are used in settlements

Sponsors often settle on a later launch date rather than litigate all claim categories.
Generic applicants may accept label carve-outs or limit indications to avoid method claim infringement.

Real-world litigation dynamic

Method-of-use patents tend to be negotiated in settlement frameworks where the sponsor has both label coverage leverage and enforceable formulation barriers.

How does ATC Class L02B compare with other oncology endocrine classes for patent defensibility?

Competitive landscape comparison

Compared with broader endocrine oncology groupings, L02B often features:
- High-value AR pathway inhibitors with dense patent estates
- Combination-based method-of-use expansion (increasing claim permutations)
- Strong formulation IP for oral exposure consistency

Key difference vs other endocrine classes

AR/androgen pathway drugs frequently use late-stage label expansion across disease stages, which increases the number of potentially relevant use patents.
SERD/SERM-adjacent assets (where included) can have distinct formulation IP, especially if delivered as injectables or requiring specialized oral delivery systems.

What patent litigation affects L02B launches most, and how do settlement agreements change risk?

Litigation categories that matter

MoC validity and infringement: determines whether generic can launch at all
Formulation infringement: can block “design-around” versions if claims are broad and the generic cannot meet alternative formulation constraints
Use patent infringement: can block label entry or trigger carve-outs that shift commercial timing

Settlement mechanics that drive market timing

Delayed generic entry dates negotiated to align with specific patent expirations.
License arrangements can permit earlier launch under defined label restrictions or royalty-bearing supply.

Which companies challenge or defend L02B patents most often?

Defender profile

Originators with dense Orange Book listings and a history of settlements:
- AstraZeneca/other holders for abiraterone (historically tied to specific originator entities)
- Medivation/Astellas/others for enzalutamide
- Janssen/others for apalutamide
- Bayer/others for darolutamide

Challenger profile

Generic majors and specialty generics that file Paragraph IV for oral oncolytics, typically with a repeat pattern across the same therapeutic area.

How to use this commercially

Map challenger companies by litigation portfolio: repeat challengers tend to have established at-risk launch capability and robust design-around programs.

What generic entry risks exist for L02B drugs, and what launch scenarios are most common?

Primary generic entry scenarios

Full launch after all Orange Book blockers expire
- Often delayed by late-expiring formulation or use patents
Launch after settlement with delayed entry
- Generic launches with agreed timing and sometimes label limitations
Design-around formulation or limited label
- Generic may attempt to enter with modified formulation or different indication carve-outs

At-risk entry

At-risk launches are more feasible where:
- Orange Book listing density is low
- Litigation history suggests invalidity or non-infringement wins for generics
- Sponsors choose not to pursue injunctions

What regulatory status do L02B drugs have in the US and EU, and how does that affect patent strategy?

US regulatory touchpoints

FDA approval type (NDA vs ANDA referencing)
Orange Book listing completeness
Exclusivity eligibility for NCE/new indication and pediatric extensions

EU regulatory touchpoints

SPC issuance and duration
National marketing authorizations with product-specific scope

Regulatory-patent interplay

Sponsors align SPC timelines with patent enforcement and label expansion. Generics and biosimilar developers align development plans with the “last date” of effective patent barriers to minimize the risk window.

Key L02B business implications by market stage

Pre-expiry

Expect continued line-extension filings: polymorph, formulation, combination use
Litigation and settlement leverage increases as first expiry dates approach

Expiry approach

Paragraph IV filings cluster around the latest effectively enforceable expiration dates
Settlement becomes more frequent when sponsors can offer label or formulation leverage

Post-expiry

Market share erosion accelerates when delayed launches settle into “effective generic availability”
Remaining differentiation shifts to:
- price
- access and contracting
- adherence support for oral regimens
- new-label expansions that keep some patients on proprietary therapy

Key Takeaways

L02B market dynamics are driven by dense, multi-layer patent estates that combine MoC, formulation/crystal control, and method-of-use expansions.
Generic entry risk is concentrated where Orange Book listings are extensive and late-expiring formulation/use patents prolong the practical blocking window.
Paragraph IV litigation and settlement agreements are the primary determinants of actual launch timing for oral L02B therapies.
Accurate exclusivity calendars must be label- and dosage-form-specific, because Orange Book coverage varies across strengths and formulation presentations.
Commercial outcomes are often governed less by first MoC expiry and more by the later “last blocking patent” category.

FAQs

How do formulation polymorph patents in ATC L02B affect ANDA design-around options for oral oncology drugs?
Which exclusivity mechanisms besides MoC term most commonly extend L02B protection in the US?
When do method-of-use patents in L02B typically create label carve-outs for generic challengers?
How do EU SPC durations change the effective entry timing for L02B products compared with US patent calendars?
What settlement structures most often determine the effective generic launch date for L02B oral therapies?

References

U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (FDA website).
U.S. Patent and Trademark Office. Patent term and adjustments overview. (USPTO website).
European Medicines Agency. Supplementary protection certificate (SPC) guidance and overview. (EMA website).

Drugs in ATC Class L02B

Subclasses in ATC: L02B - HORMONE ANTAGONISTS AND RELATED AGENTS

Market Dynamics and Patent Landscape for ATC Class L02B (Hormone Antagonists and Related Agents): Exclusivity Timelines, Orange Book Status, and Generic/Biosimilar Risk